Bionor’s 3rd vaccine candidate, CRX, Proof of Mechanism established

Oslo, January 23, 2019. Bionor is pleased to announce that Proof of Mechanism is established for our 3rd vaccine candidate, CRX. This product aims to prevent binding between gp120 V3 loop and CCR5/CXCR4 coreceptors and facilitate virus neutralization. Lead optimization and drug characterization with Proof of Principle will be established within the next 6 – …

Read more

New strategy for combining Vacc-4x and Vacc-C5 with a defined path that can lead to a regulatory approval and commercialization

Bionor’s strategy is to develop the combination of its two proprietary therapeutic HIV vaccines Vacc-4x and Vacc-C5 and seek advice on and adapt its regulatory path so that a marketing approval for a functional cure for HIV can be achieved. As part of this strategy, Bionor will extend and complete the Vacc-C5 dose escalation studies …

Read more